Post-operative plasma osteopontin predicts distant metastasis in human colorectal cancer by Chow, AKM et al.
Title Post-operative plasma osteopontin predicts distant metastasisin human colorectal cancer
Author(s)
Ng, L; Wan, TMH; Lam, CSC; Chow, AKM; Wong, SKM; Man,
JHW; Li, HS; Cheng, NSM; Pak, RCH; Cheung, AHK; Yau, TCC;
Lo, OSH; Foo, DCC; Poon, TCJ; Poon, RTP; Pang, RWC; Law,
WL
Citation PloS one, 2015, v. 10 n. 5, p. e0126219
Issued Date 2015
URL http://hdl.handle.net/10722/211947
Rights Creative Commons: Attribution 3.0 Hong Kong License
RESEARCH ARTICLE
Post-Operative Plasma Osteopontin Predicts
Distant Metastasis in Human Colorectal
Cancer
Lui Ng1, Timothy Ming-HunWan1, Colin Siu-Chi Lam1, Ariel Ka-Man Chow1,2, Sunny Kit-
ManWong1, Johnny Hon-Wai Man1, Hung-Sing Li1, Nathan Shiu-Man Cheng1, Ryan
Chung-Hei Pak1, Alvin Ho-Kwan Cheung1, Thomas Chung-Cheung Yau1,2, Oswens Siu-
Hung Lo1, Dominic Chi-Chung Foo1, Jensen Tung-Chung Poon1, Ronnie Tung-
Ping Poon1,2, Roberta Wen-Chi Pang1,2*, Wai-Lun Law1
1 Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR,
China, 2 Centre for Cancer Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong
Kong SAR, China
* robertap@hku.hk
Abstract
Background
The overall prognosis of colorectal cancer (CRC) patients is unsatisfactory due to cancer
metastasis after operation. This study aims to investigate the clinical significance of plasma
osteopontin (OPN) levels as minimally invasive, predictive, and surrogate biomarkers for
prognosis of CRC patients.
Methods
This randomized study design consists of pre-operative and post-operative plasma samples
from a total of 79 patients. We determined plasma levels of OPN by ELISA and examined
their correlation with the clinicopathological parameters of CRC patients. The effects of en-
dogenous and exogenous OPN on CRCmetastasis were investigated by examination of
the effect on regulators of epithelial to messenchymal transition and migration assay.
Results
Our findings demonstrated for the first time the clinical correlation of plasma OPN with me-
tastasis of CRC patients. High post-operative plasma OPN level (>153.02 ng/ml) associat-
ed with development of metastasis after curative resection (p<0.001). Moreover, post-
operative plasma OPN level correlated with disease-free survival of CRC patients
(p=0.009) and was an independent factor for predicting development of metastasis in CRC
patients after curative resection (p=0.036). Our in vitromodel showed that OPN ectopic ex-
pression induced DLD1 cell migration through Snail and Twist1 overexpression and E-cad-
herin repression, and secretory OPN level enhanced cell migration.
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Conclusions
The results of the current study suggest that post-operative plasma OPN correlated with
post-operative metastasis, suggesting that it is a potential non-invasive biomarker for the
development of future metastasis in CRC patients. In addition, OPN was shown to be in-
volved in the metastatic process and thus inhibition of OPN is a potential therapeutic ap-
proach to treat CRC patients.
Introduction
Colorectal cancer (CRC) is the third most common malignancy around the world [1]. Annual-
ly, over 1.2 million people develop CRC globally, with more than 600,000 patients die from the
disease in 2008 [2]. Incidence and mortality rates for CRC have declined as a result of improved
tests that allow early detection of the cancer, when it can be more easily treated by surgery and
chemotherapy along with radiotherapy [3]. Despite those advances in clinical treatment, the
overall prognosis of CRC patients is still unsatisfactory due to cancer metastasis. Therefore, it
is important to develop additional biomarkers in order to enhance the prognosis of CRC pa-
tients by prediction or early detection of occult metastasis.
Blood-based, minimally invasive markers would be increasing important in CRC screening
and monitoring of CRC patients. Carcinoembryonic antigen (CEA) and CA19-9 have been
commonly assessed in CRC patients, but with varying results depending on the study design
and the study population [4], and their clinical association with cancer metastasis have not
been demonstrated thus far. Although numerous biomarkers are under evaluation for the de-
tection of CRC from serum, none of them has sufficient sensitivity and specificity to be consid-
ered in the current guidelines [4].
Osteopontin (OPN) is a secreted glycoprotein with a multi-domain structure and functions
characteristic of an extracellular protein [5]. It is a small integrin-binding ligand N-linked gly-
coprotein (SIBLING) that binds to cell surface receptors including integrins and CD44 [6].
OPN is expressed in many tissues and secreted into body fluids, including blood, milk and
urine [7–9], which has important physiological roles in bone remodeling, immune response
and inflammation [10]. It is also a tumor-associated protein and elevated OPN levels are asso-
ciated with cellular proliferation, invasion and angiogenesis via altered activity of matrix metal-
loproteinases, the epidermal growth factor receptor and PI3K-AKT signaling [11, 12]. These
preclinical studies suggest that plasma OPN could be an important non-invasive biomarker of
occult systemic metastases. In accordance, in a recent meta-analysis of over 228 publications,
high tumor or plasma OPN levels correlated with decreased disease-free survival and overall
survival in multiple tumor types, including lung cancer, breast cancer, prostate cancer, head
and neck cancer and liver cancer [13].
Increased levels of OPN mRNA and protein have been demonstrated in CRC comparing to
the non-tumor tissue [14–17], and the high expression correlated with metastatic features such
as lymph node metastasis and distant metastasis [17]. However, Nitsche et al’s study which in-
vestigated more than 200 patients with stage II colon cancer demonstrated that tumor tissue
level of osteopontin was useful for detecting the presence of colon cancer, but not for predicting
the prognosis of the patients [18]. These studies suggested that OPN tissue level was not yet
confirmative to detect or predict CRC metastasis. Blood OPN level has been suggested as a po-
tential detective biomarker of CRC, yet its clinical correlation with CRC metastasis has not
been demonstrated thus far. In addition, most of the cancer studies focused on the clinical
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significance of pre-operative plasma OPN level, while the post-operative level in cancer pa-
tients has seldom been investigated. Therefore, in this study, we will examine the clinicopatho-
gical significance as well as the prognostic potential of pre-operative and post-operative plasma
OPN levels of CRC patients.
Materials and Methods
Patients and specimens
The human sample collection protocol has been approved by the Institutional Review Board
(IRB) of the University of Hong Kong, and all clinical investigation has been conducted accord-
ing to the principles expressed in the Declaration of Helsinki. Informed written consent has
been obtained from the participants. Pre-operative blood samples were obtained from 96 pa-
tients who underwent surgical resection of primary CRC at the Department of Surgery, Queen
Mary Hospital, The University of Hong Kong, between 1998 and 2007. Tissue samples were
obtained from 32 out of the 96 patients, immediately frozen in liquid nitrogen and kept at
-80°C until analysis. The post-operative blood was obtained from patients during their post-
operative follow-up visit to our clinic (usually within 6 months after surgical operation). Blood
was anticoagulated by EDTA and then centrifuged at 2,500 rpm for 10 min. The plasma was
collected, aliquoted, and snap frozen at -80°C till use. Clinicopathological data and blood CEA
level were obtained from the patient database of our hospital.
Enzyme-linked immunosorbent assay
Plasma level of OPN or secretory OPN level in CRC cell-lines were measured using a commer-
cial enzyme-linked immunosorbent assay kit (R&D Systems, Inc., Minneapolis, MN) and
100 μl of diluted (1:125) plasma samples/200 μl of diluted cell-culture media. The plates were
firstly coated with OPN capture antibody overnight. After three washes with PBS-0.5% tween
20, the plates were blocked with 1% filtered BSA in PBS for 1 hour. 0.1 mL of each sample was
added to the plate and incubated for 2 hours at room temperature, followed by addition of
100 μl OPN biotinylated antibody and incubated for 2 hours at room temperature. After three
washes, 100 μl of horseradish-conjugated strepavidin solution was added and incubated for 20
minutes at room temperature. Finally, 100 μl of tetramethylbenzidine substrate solution was
added and incubated for 5 minutes in the dark, followed by the addition of 50 μl of stop solu-
tion. Absorbance was measured at 450 nm with wavelength correction at 570 nm.
RNA extraction and DNase I treatment
Total RNA was extracted using Trizol reagent and Purelink RNAmini kit (Life Technologies,
Carlsbad, CA). Briefly, 50–100 mg of frozen tissue sample was homogenized in 1 ml Trizol Re-
agent using a homogenizer, whereas cells adherent on culture dish were directly lysed by add-
ing 1 ml of Trizol Reagent, pipetting the lysates several times, and transferring to a sterile 1.5
ml centrifuge tube. Following 5 min of incubation at room temperature, 0.2 ml chloroform per
1 ml Trizol Reagent used was added and the tube was shaken vigorously by hand for 15 sec.
Following 3 min-incubation, the sample was centrifuged at 12,000 x g for 15 min. The colorless
upper aqueous phase was transferred to a new sterile tube and equal volume of 70% ethanol
was added and the mixture was mixed well. The sample was transferred to a spin cartridge and
centrifuged at 12,000 x g for 15 sec at room temperature, followed by washing step with 700 μl
Wash Buffer I once and 500 μl Wash Buffer II twice. The spin cartridge was dried by centrifu-
gation at 12,000 x g for 1 min. 30 μl RNased-Free water was added to the spin cartridge, incu-
bated for 1 min and RNA was eluted in a new tube by centrifugation at 12,000 x g for 2 min.
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The RNA was then proceeded to DNase I digestion by adding 3 μl 10X DNase I buffer and 3 μl
DNased I, Amplification Grade (Life technologies) to 24 μl RNA sample. Following 15 min-in-
cubation at room temperature, RNA was purified using Purelink RNA mini kit (Life Technolo-
gies). Briefly, 1 volume of freshly prepared lysis buffer with 2–mercaptoethanol (10 μl per 1 ml
lysis buffer) and one volume of absolute ethanol was added to each RNA sample and mixed
well. The sample was transferred to a spin cartridge and centrifuged at 12,000 x g for 15 sec at
room temperature, followed by washing step with 700 μl Wash Buffer I once and 500 μl Wash
Buffer II twice. The spin cartridge was dried by centrifugation at 12,000 x g for 1 min. 30 μl
RNased-Free water was added to the spin cartridge, incubated for 1 min and RNA was eluted
in a new tube by centrifugation at 12,000 x g for 2 min. The RNA yield and quality were ana-
lyzed by NanoDrop 2000 (Thermo Scientific).
cDNA synthesis and quantitative real-time polymerase chain reaction
2.0 μg total RNA was reverse-transcribed with SuperScriptII RT-PCR kit (Invitrogen, Carlsbad,
CA) in accordance with the instructions of the manufacturer. Real-time PCR was performed in
a final volume of 15 μl containing 1.5 μl RT transcript, 0.2 μM of each primer, 1X ROX refer-
ence dye and 7.5 μl of FastStart Universal SYBR Green Master (ROX) (Roche Diagnostics,
Switzerland, Basel). A no RT transcript control was included for each gene to ensure the signal
was truly driven by target gene amplification. The primer sequences were as follows: OPN-For-
ward Primer: 5’-TGGGGGTCACTGCAATTAG-3, OPN-Reverse Primer: ‘5’-TGGGGCTAG
GAGATTCTG-3’; E-cadherin-Forward Primer: 5’- TGGAGGAATTCTTGCTTTGC-3’; E-
cadherin-Reverse Primer: 5’- CGTACATGTCAGCCAGCTT-3’; Snail-Forward Primer: 5’-
CAGACCCACTCAGATGTCAA-3’, Snail-Reverse Primer: 5’-CATAGTTAGTCACACCTCGT-
3’; Twist1-Forward Primer: 5’- GGGAGTCCGCAGTCTTAC-3’, Twist1-Reverse Primer:
5’- CCTGTCTCGCTTTCTC-TTT-3’; GAPDH- Forward Primer: 5’-
GTCTCCTCTGACTTCAACAGCG -3’, GAPDH- Reverse Primer: 5’- ACCACCCTGTTGCTG
TAGCCAA -3’. Real-time PCR was carried out using the ABI 7900HT Fast Real-Time PCR
System (Applied Biosystems, Foster, CA) at 95°C for 10 min, followed by 40 cycles at 95°C for
15 sec and at 56°C for 1 min. Each assay was done in triplicate, the average was calculated and
the expression level of target mRNA was expressed as fold to expression of GAPDH. For cell-
line experiments, fold-change was calculated based on the change in abundance of transcript of
interest (normalized to GAPDH) from experimental group compared to the abundance of
transcript of interest (normalized to GAPDH) from control group.
Plasmid construction
OPN full-length coding sequence was amplified by OPN-Kpn I-Forward Primer
CGGGGTACCGTGCCAGCCAAACAACAAA and OPN-Xba I-Reverse Primer TGCTCTAGATG
CAAAGTGAGAAATTGTATTT, using Platinum Taq DNA Polymerase High Fidelity (Life Tech-
noloies) according to the manufacturer’s instruction. The PCR cycle was 94°C for 2 min, fol-
lowed by 30 cycles of 94°C for 30 sec, 56°C for 30 sec and 68°C for 2 min. The OPN PCR
product was purified by Qiagen PCR purification system (Valencia, CA, USA) according to the
manufacturer’s protocol. The pcDNA3.1 vector (Invitrogen) and OPN purified PCR products
were digested by KpnI and XbaI restriction enzymes (New England Biolabs), purified and ligat-
ed by DNA ligase (New England Biolabs). The ligation product was transformed into DH5α
competent cells (Life Technologies) according to the manufacturer’s instructions. The plasmids
were extracted by the Qiaprep Spin Miniprep Kit (Qiagen) sequence fidelity was confirmed by
DNA sequencing.
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Cell-lines, tissue culture, transfections and reagents
CRC cell-lines were maintained in DMEM with 10% fetal bovine serum and antibiotics (Invi-
trogen, Carlsbad, CA), 5% CO2 at 37°C. DLD1 and SW480 cells were transiently transfected
with vector control or OPN expression plasmid using Lipofectamine 2000 reagent (Invitrogen)
according to the manufacturer’s instructions. DLD1-OPN1 and vector control stable clones
were generated by selection in culture medium containing 1 mg/ml G418 (Roche) for 3 weeks.
HCT116 and SW620 cells were transiently transfected with siRNA negative control or OPN
siRNA oligonucleotides (Invitrogen) using Lipofectamine 3000 reagent (Invitrogen) according
to the manufacturer’s instructions.
Protein extraction and western blot analysis
Cell-lines were harvested, collected and lysed in RIPA buffer (Cell Signaling Technology, Dan-
vers, MA) containing 1 mmol/L phenoylmethylsulfonyl fluoride for 1 hour on ice. The lysate
was centrifuge at 12,000 x g for 15 min and supernatant was transferred to a new sterile tube.
The protein concentration was determined using BCA Protein Assay Kit (Thermo Scientific).
Lysed protein was suspended in sodium dodecyl sulfate sample buffer, boiled, resolved in sodi-
um dodecyl sulfate—polyacrylamide gel electrophoresis, and transferred to PVDF membranes
(GE Healthcare, Piscataway, NJ). Antibodies against E-cadherin and GAPDH (for normaliza-
tion) were purchased from Cell Signaling Technology (Danvers, MA). Representative Western
blots of experiments that were repeated 3 times are shown. Densitonmetry was performed on
the western blots using ImageJ software.
In vitromigration and invasion assay
Cells were harvested, resuspended in serum-free medium and seeded into transwell chamber
(Corning or BD Biosciences). Two hundred and fifty microliters of a 50000 cell suspension in
serum-free medium were added to the upper chamber which was placed into a 24-well plate
with the bottom filled with 750 μl complete medium as a chemoattractant. After 3 days the
number of cells migrated was determined according to the manufacturer’s instructions. Each
experiment was done in duplicate, and results were presented as the mean ± SD of three
independent experiments.
Statistical analysis
The association of plasma OPN levels with continuous variables was tested with Pearson’s cor-
relation. Student’s t-test was applied to compare difference between two groups. Differences in
recurrence rates in different groups of patients with CRC were evaluated by the fisher exact
test. Disease-free survival was analyzed using the Kaplan—Meier product limit method and
log-rank test. Univariate and multivariate analyses in a Cox proportional-hazards model for
prognostic predictors were performed. All of these statistical analyses were performed with Sig-
maPlot 10.0 (Systat Software Inc., San Jose, CA, USA) or SPSS 10.0 software (SPSS, Inc., Chi-
cago, IL, USA). Statistical significance was set at p 0.05.
Results
Comparison of plasma OPN level between normal donors and CRC
patients
We first determined the plasma OPN level from 56 normal donors and 83 CRC patients before
surgical resection of their tumors. The mean plasma OPN level of CRC patients was 160.31 ng/
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ml, which was significantly higher than that of normal donors (115.27 ng/ml; p<0.001). We
further divided the patients into early stage (stage I to II, n = 45) and advance stage (stage III to
IV, n = 38). The mean plasma OPN level of advance stage patients (187.91 ng/ml) was signifi-
cantly higher than that of normal donors (p<0.001), whereas level of early stage patients
(137.00 ng/ml) was insignificantly higher (p = 0.052). These results suggested that plasma OPN
could be a non-invasive biomarker for screening CRC patients with advance tumor stage, but
its sensitivity decreased in screening early stage CRC patients.
Correlation of pre-operative plasma OPN level with OPN transcript
expression and clinicopathological parameters
We next examined the correlation between the pre-operative plasma OPN level and the paired
tumor OPN transcript level in 32 CRC patients. As shown in Fig 1A, there was a positive corre-
lation between the OPN level in plasma and CRC tumor (R = 0.452, p = 0.0010), suggesting
that plasma OPN level in CRC patients was indicative of their CRC OPN expression. We then
examined the correlation of pre-operative plasma OPN level of 83 CRC patients with their
clinicopathological data (Table 1). Plasma OPN level did not correlate with age, gender and
lymph node metastasis. Significantly higher plasma OPN level was detected in patients with
tumor size over 5 cm (180.4 vs 140.7 ng/ml, p = 0.003; 1C), higher stage (187.9 vs 137.0 ng/ml,
p<0.001; Fig 1D) and metastatic CRC (197.0 vs 148.7 ng/ml, p = 0.003; Fig 1E). The pre-opera-
tive plasma OPN level also positively correlated with tumor size (R = 0.390, p<0.001; Fig 1B).
These results revealed that pre-operative plasma OPN was a potential non-invasive biomarker
for tumor progression and metastasis. We also examined whether pre-operative plasma OPN
level correlated with future metastasis of CRC patients who showed no distant metastasis at op-
eration. Our results showed that such level showed no significant difference between patients
with and without future metastasis (132.09 vs 130.63 ng/ml, p = 0.951; Fig 1F), indicating that
pre-operative plasma OPN level was not prognostic for future metastasis.
Clinical significance of post-operative plasma OPN levels
We next studied the prognostic value of post-operative plasma OPN level for the development
of post-operative metastasis in another cohort of 89 CRC patients. 40 of them developed post-
operative metastasis within 30 months, and these patients displayed significantly higher post-
operative plasma OPN level than the 49 non-metastatic patients (187.0 vs 145.7 ng/ml,
p = 0.004; Fig 2A). Applying the overall median post-operative plasma OPN level (153.02 ng/
ml) of CRC patients in this study as the threshold value, CRC patients with high post-operative
plasma OPN level were more likely to develop distant metastasis (29 out of the 45 patients)
than those with low post-operative plasma OPN level (11 out of 44, p<0.01; Fig 2B). To illus-
trate the performance of the post-operative plasma OPN as prediction biomarker, ROC curve
was constructed. The area under curve (AUC) of the ROC curve was 0.711 (Fig 2C, 95% CI:
0.601 to 0.821), and the sensitivity and specificity were 0.700 and 0.694, respectively.
Comparison of prognostic significance between plasma OPN and blood
CEA
To confirm that post-operative plasma OPN level was an important prognostic factor for fu-
ture metastasis, we examined the prognostic values of post-operative plasma OPN level and
pre-operative plasma OPN level for disease-free survival (DFS) of 44 stage I to III CRC patients
with thorough operation and follow-up information. Stage IV CRC patients where distal me-
tastasis can be present before surgery were excluded from this analysis. As shown in Fig 2D,
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Fig 1. Clinicopathological significances of pre-operative plasma OPN level. (A) Correlation of pre-operative plasma OPN level with the paired tumor
OPN transcript level in 32 CRC patients (R = 0.452, p = 0.010; Pearson correlation). (B) Correlation of pre-operative plasma OPN level with tumor size
(R = 0.390, p<0.001; Pearson correlation). (C) Comparison of pre-operative plasma OPN levels in patients with tumor5 or <5 (p = 0.003; Student’s t-test)
(left). (D) Comparison of pre-operative plasma OPN levels in patients with lower (I to II) or higher stage (III to IV) (p<0.001; Student’s t-test). (E) Comparison of
pre-operative plasma OPN levels in patients with or without distant metastasis (p = 0.003; Student’s t-test). (F) Comparison of pre-operative plasmaOPN
levels in patients with or without post-operative metastasis (p = 0.951; Student’s t-test). All data are representative of three independent experiments.
doi:10.1371/journal.pone.0126219.g001
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CRC patients with lower post-operative plasma OPN level showed a significantly longer DFS
than those over the threshold level (p = 0.009), whereas pre-operative plasma OPN level did
not correlate with DFS of CRC patients (S1 Fig). We also examined the prognostic value of
CEA levels (S1 Fig). Neither pre-operative nor post-operative CEA correlated with DFS
(p = 0.235 and 0.410, respectively).
Risk factors for disease-free survival of CRC patients
We applied univariate and multivariate analyses to determine the risk factors for DFS of the
above 44 CRC patients (Table 2). Among the clinical factors examined in the univariate analy-
sis, only post-operative plasma OPN level was significantly correlated with DFS. In addition,
our multivariate analysis showed that post-operative OPN level and lymph node metastasis
were risk factors for DFS.
In vitro effect of elevated OPN transcript and secretory OPN levels
Finally, we investigated the in vitro effects of OPN overexpression on secretory OPN level and
metastatic feature of CRC cells. We first compared the transcriptional and secretory OPN levels
of two relatively non-metastatic cell-lines DLD1 and SW480, and two metastatic cell-lines
SW620 and HCT116 [19, 20]. After 3 days, both levels were significantly lower for DLD1 and
SW480 cells when compared with SW620 and HCT116 cells (Fig 3A and 3B), suggesting that
OPN transcript level correlated with its secretory level, and high OPN level correlated with the
metastatic potential of CRC cells. We next stably overexpressed OPN in DLD1 cells and gener-
ated two stable OPN transfectants (DLD1-OPN#1 and DLD1-OPN#3), both expressed higher
level of OPN transcript, protein and secretory protein than the DLD1-vector control (Figs 3C,
3E and 4A). We determined the effect on proliferation, cell invasion and cell migration. Our re-
sults showed that OPN overexpression significantly induced cell migration in DLD1 cells (Fig
4B), but did not alter the growth rate and cell invasion ability (S2 Fig). To confirm the effect of
OPN on cell migration, we transiently knock-down OPN expression in DLD1-OPN stable
clone by siRNA technique. Comparing to siRNA control transfected cells, DLD1-OPN cells
transfected with siOPN displayed significantly lower level of OPN transcript and protein as
well as secretory OPN protein (Figs 3D, 3E and 4D). More importantly, the migration rate was
Table 1. Clinicopatholgical Correlation of Pre-operative Plasma OPN level (N = 83).
Clinicopathological features Category Number of cases* Pre-operative plasma OPN level (ng/ml) (Mean ± SEM) p value
Age <65 32 153.5 ± 10.17 0.446
> or = 65 51 164.6 ± 9.45
Gender Male 58 155.7 ± 7.40 0.319
Female 25 171.0 ± 15.71
Tumor Size < 5 cm 44 140.7 ± 8.23 0.003
 5 cm 36 180.4 ± 11.52
Lymph node metastasis Absent 37 158.1 ± 11.29 0.618
Present 41 165.5 ± 9.51
Tumor AJCC stage I to II 45 137.0 ± 7.27 0.001
III to IV 38 187.9 ± 11.16
Distant metastasis Absent 63 148.7 ± 7.20 0.003
Present 20 197.0 ± 15.80
*In some category, the total number of cases is less than 83 due to incomplete information.
doi:10.1371/journal.pone.0126219.t001
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also significantly repressed following siOPN transfection (Fig 4E), strengthening the regulatory
role of OPN on cell migration. Furthermore, we examined the effect of secretory OPN level on
cell migration by applying culture medium from DLD1-OPN stable clones or vector control
(1:1 mixed with fresh culture medium) as chemoattractant for cell migration assay using DLD1
cell as model. We found that culture medium with higher OPN level significantly induced
DLD1 cell migration (Fig 4C). In addition, DLD1 cell migration was significantly impaired
using culture medium of siOPN transfected DLD1-OPN#1 cells when compared with that of
siCTL transfected cells (Fig 4F).
Fig 2. Clinicopathological significances of post-operative plasma OPN level. (A) Comparison of post-operative plasma OPN levels in patients with or
without post-operative metastasis (p = 0.004; Student’s t-test). (B) Incidence rates of post-operative metastasis in CRC patients with high (153.02 ng/ml) or
low (<153.02 ng/ml) post-operative plasma OPN level. (C) ROC curve using post-operative plasma OPN level for discriminating patients with post-operative
metastasis from those without post-operative metastasis. (D) Correlation of post-operative plasma OPN with disease-free survival of CRC patients
(p = 0.009; Log-rank test). All data are representative of three independent experiments.
doi:10.1371/journal.pone.0126219.g002
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In addition, our results demonstrated that overexpression of OPN in DLD1 cells significant-
ly induced the transcription of Snail and Twist, which are inducers of epithelial-to-mesenchy-
mal transition (EMT) process by down-regulating E-cadherin and promoting cell migration,
invasion and metastasis [21–23]. As expected, the transcript and protein levels of E-cadherin
were significantly reduced in DLD1-OPN stable clones (Fig 3C–3E). On the other hand, fol-
lowing siOPN transfection, the transcription of Snail and Twist was repressed, and resulted in
elevation of E-cadherin transcription and translation (Fig 3D and 3E). These results suggested
that induction of the EMT process is responsible for the enhanced cell migration of OPN-over-
expressing DLD1 cells.
Discussion
The overall prognosis of CRC patients is still unsatisfactory due to cancer metastasis, hence, it
is important to develop additional biomarkers in order to enhance the prognosis of CRC pa-
tients by prediction or early detection of occult metastasis. Blood-based, minimally invasive
markers would be increasing important due to the ease and convenience of sample collection.
Blood CEA and CA19-9 have been commonly assessed in CRC patients, but with varying re-
sults depending on the study design and the study population [4], and their clinical association
with cancer metastasis is lacking. Therefore, we believe that development of additional blood-
based biomarker would be crucial for improving the prognosis of metastatic CRC patients.
Increased levels of OPN mRNA and protein have been demonstrated in CRC comparing to
the non-tumor tissue [14–17]. OPN expression is regulated by a wide variety of stimuli which
are associated with CRC progression and metastasis [24–27], involving complex regulatory
Table 2. Univariate andmultivariate analyses of prognostic factors for disease-free survival of CRC
patients.
Univariate analysis Relative risk (95% confidence interval) p-value
Age, year (<65 versus 65) 0.766 (0.090–6.497) 0.807
Gender (female versus male) 0.255 (0.049–1.340) 0.107
Tumor Size ( 5 versus< 5) 1.635 (0.408–6.554) 0.488
Tumor stage (III versus I to II) 3.054 (0.609–15.310) 0.175
Lymph node metastasis (yes versus no) 1.305 (0.324–5.256) 0.708
Pre-operative CEA level (high versus low) 2.960 (0.594–14.765) 0.186
Post-operative CEA level (high versus low) 1.466 (0.347–6.194) 0.603
Pre-operative OPN level (high versus low) 2.167 (0.513–9.158) 0.293
Post-operative OPN level (high versus low) 14.656 (1.748–122.866) * 0.013
Multivariate analysis Relative risk (95% confidence interval) p-value
Age, year ( 65 versus< 65) NA
Gender (female versus male) NA
Tumor Size ( 5 versus< 5) NA
Tumor stage (III to IV versus I to II) NA
Lymph node metastasis (yes versus no) 13.367 (1.017–175.646) *0.045
Pre-operative CEA level (high versus low) NA
Post-operative CEA level (high versus low) NA
Pre-operative OPN level (high versus low) NA
Post-operative OPN level (high versus low) 191.091 (1.401–2.606E4) *0.036
Note:
* indicates the difference is statistically significant
doi:10.1371/journal.pone.0126219.t002
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Fig 3. Molecular effects of OPN on EMT regulators. (A and B) Comparison of (A) transcriptional and (B) secretory OPN levels of two weakly metastatic
CRC cell-lines (DLD1 and SW480) and two metastatic CRC cell-lines (SW620 and HCT116) (One way ANOVA). (C)OPNmRNA expression of two
DLD1-OPN stable clones (DLD1-OPN#1 and #3) and vector control (DLD1-Vector) and effect of stable OPN overexpression on mRNA expression of EMT
regulators E-cadherin, Twist and Snail (One way ANOVA). (D)OPNmRNA expression of siCTL or siOPN transfected DLD1-OPN#1 cells and effect of OPN
siRNA on mRNA expression of EMT regulators E-cadherin, Twist and Snail (Student’s t-test). (E) Effect of OPN overexpression or siRNA on E-cadherin
protein expression. GAPDH served as loading control. Densitometry was performed on the western blots using the ImageJ software and an asterisk
indicates the difference was statistically significant (p<0.05) when compared with the control (DLD1-V1 or DLD1-OPN1 siCTL; One way ANOVA or Student’s
t-test). All data are representative of three independent experiments.
doi:10.1371/journal.pone.0126219.g003
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pathways. Various growth and differentiation factors also increase OPN expression, including
platelet-derived growth factor, epidermal growth factor, transforming growth factor-β, bone
morphogenic proteins and inflammatory cytokines [28]. In addition, transcription of OPN is
also directly activated by a number of transcriptional regulators including Wnt signaling and
Tcf-4 [28], which is a well-known deregulated pathway promoting CRC. In the presence of β-
catenin, Tcf-4 cooperates to stimulate OPN promoter activation and protein production [29].
We believed that the activation of these factors and signaling pathway during CRC tumor pro-
gression induces OPN expression and the subsequent cancer cell metastasis.
Plasma OPN is a potential non-invasive prognostic marker for tumor progression, invasion
and metastasis in gastrointestinal cancers [30]. While high plasma OPN level has been associat-
ed with metastatic features in a variety of cancers such as gastric cancer [31], hepatocellular
carcinoma, esophageal squamous cell carcinoma [32], renal cell carcinoma [33], prostate can-
cer [34] and breast cancer patients [35], its correlation with CRC metastasis has not been
Fig 4. Functional effects of OPN on CRC cell migration. (A) Comparison of relative secretory OPN levels of two DLD1-OPN stable clones (DLD1-OPN#1
and #3) with that of DLD1-vector control (One way ANOVA). (B) Comparison of number of DLD1-OPN stable clones (DLD1-OPN#1 and #3) cells migrated
with that of DLD1-vector control cells (One way ANOVA). (C) Comparison of number of DLD1 cells migrated using culture medium from DLD1-OPN stable
clones (DLD1-OPN#1 and #3) or DLD1-vector control as chemoattractant (One way ANOVA). (D) Comparison of relative secretory OPN levels of
DLD1-OPN#1 stable clone transfected with siRNA control (siCTL) or OPN siRNA (siOPN) (Student’s t-test). (E) Effect of siCTL or OPN siRNA transfection on
migration of DLD1-OPN#1 stable cells (Student’s t-test). (F) Comparison of number of DLD1 cells migrated using culture medium from DLD1-OPN stable
clones transfected with siCTL or siOPN as chemoattractant (Student’s t-test). All data are representative of three independent experiments.
doi:10.1371/journal.pone.0126219.g004
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demonstrated thus far. The present study aims to examine the potential of plasma OPN levels
as a diagnostic and prognostic biomarker of CRC.
This study showed that the post-operative plasma OPN level could predict the development
of future metastasis in CRC patients. While most of the studies on OPN focused on the clinical
significance of pre-operative plasma OPN level in cancer patients, the post-operative level has
seldom been investigated. A recent HCC study which demonstrated post-operative serum
OPN level could serve as surrogate serologic biomarker for monitoring treatment response and
tumor recurrence [36], indicating the potential of post-operative plasma OPN as biomarker in
HCC and other cancers. Our results demonstrated a significantly higher post-operative plasma
OPN level in CRC patients with post-operative distant metastasis and shorter DFS, when com-
pared with those bearing low post-operative plasma OPN level. We further showed that neither
pre-operative nor post-operative CEA level was prognostic for development of post-operative
metastasis, suggesting that in addition to CEA, other blood parameters (such as plasma OPN)
are necessary to monitor the disease progression status of CRC patients.
Our results revealed that pre-operative plasma OPN level correlated with tumor size and
distant metastasis. One possible explanation to such correlation is that plasma OPN level asso-
ciates with treatment response of chemotherapy. In a non-small cell lung cancer clinical study,
high pre-operative plasma OPN level was significantly associated with patient response, pro-
gression-free survival, and overall survival in patients receiving platinum-based chemotherapy
[37]. In another colorectal cancer study which employed plasma OPN in their six-marker sig-
nature, they demonstrated the predictive importance of their six-marker signature for CRC pa-
tients treated with bevacizumab in combination with capecitabine/oxaliplatin [32]. Since
oxaliplatin/cisplatin-based chemotherapy is widely applied to CRC patients, their findings sug-
gest that patients bearing higher plasma OPN are more resistant to those treatments and thus
more susceptible to tumor progression and distant metastasis.
Moreover, our study demonstrated that high pre-operative plasma OPN level was associated
with metastasis at the time of surgical operation while high post-operative level correlated with
development of distant metastasis after primary resection. The functional effects of endoge-
nous and exogenous OPN in induction of CRC cell growth, angiogenesis, invasion and migra-
tion have been demonstrated both in vitro and in vivo [16, 38]. Our in vitro experiments also
showed that overexpression of OPN induced cell migration in CRC cell-lines DLD1 through
induction of EMT. However, no significant change was observed in the cell invasion assay, sug-
gesting that OPN is not the unique factor necessary to stimulate invasion. Similar observation
that certain factors regulate cell migration but not invasion has been reported by other cancer
studies [39, 40]. DLD1 cells migrated faster when cultured in medium with higher secretory
OPN level, indicating that OPN was not only a biomarker but also involved in the metastatic
process. Secretory OPN is more likely to play a crucial role in liver metastasis of CRC cancer
cells, since the two known receptors of OPN (integrin αv and CD44v6 proteins) are strongly
expressed in hepatocytes from normal liver [41]. We believed that inhibitor targeting OPN is a
potential therapeutic approach to treat CRC patients. A recent study demonstrated the efficacy
of a humanized anti-OPN antibody in inhibiting breast cancer growth and metastasis in vivo
[42], the efficacy of targeting OPN in CRC treatment by this anti-OPN antibody or other inhib-
itors warrants further investigations.
Plasma OPN has also been extensively investigated and shown to be a valuable biomarker in
non-small-cell lung cancer (NSCLC) patients. Its level increased in early NSCLC, reduced after
resection and increased with recurrence [43]. In chemotherapy-treated patients with advanced
NSCLC, low plasma levels of OPN were significantly associated with improved clinical out-
comes. Patients with lower levels had better response rates and higher overall and progression-
free survival rates, suggesting that OPN plasma level have utility as a prognostic biomarker in
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chemotherapy-treated patients with unresectable NSCLC [37]. A more recent NSCLC study
demonstrated that OPN level changes over time, particularly post-treatment, may yield addi-
tional prognostic information in curative-intent radiotherapy of NSCLC, which might be po-
tentially useful in the identification of patients with high risk of death and relapse after
radiotherapy. This could be beneficial in patient stratification and the decision-making process
for post-radiotherapy treatment concepts. We believed that plasma OPN is a valuable biomark-
er in CRC. The pre-operative plasma OPN level could be applied to predict the treatment re-
sponse to chemotherapy for patients with unresectable CRC, whereas the post-operative
plasma OPN level could predict and monitor the response to adjuvant chemotherapy, and
early detection of recurrence and metastasis. Extensive care and alternative treatment approach
should be taken for CRC patients who show high or increasing plasma OPN level.
To conclude, this study demonstrated high post-operative OPN after surgery were correlat-
ed with post-operative distant metastasis, suggesting that post-operative plasma OPN level is a
potential non-invasive biomarker for monitoring of CRC patients after curative resection of
their primary tumor.
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